A second cysteinyl leukotriene receptor in human lung

Area of Science:

• Pharmacology
• Respiratory Medicine
• Molecular Biology

Background:

• Leukotrienes (LTs) are key mediators of bronchoconstriction and vascular tone.
• Cysteinyl LTs, including LTC4, LTD4, and LTE4, play significant roles in respiratory diseases.
• Understanding LT receptor subtypes is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the presence and characteristics of leukotriene receptors in human bronchial and pulmonary venous smooth muscle.
• To differentiate the pharmacological profiles of cysteinyl LT receptor antagonists in airway and vascular tissues.
• To provide evidence for the existence of distinct cysteinyl LT receptor subtypes in the human lung.

Main Methods:

• Utilized isolated human bronchial and pulmonary vein preparations.
• Assessed the effects of various leukotrienes (LTC4, LTD4, LTE4) and their antagonists (ICI 198615, MK 571, SKF 104353, BAY u9773) on smooth muscle contraction.
• Determined pD2, pKB, and pKp values to characterize receptor-ligand interactions.

Main Results:

• Specific LT-1 antagonists (ICI 198615, MK 571, SKF 104353) effectively inhibited LT-induced contractions in airways but not in pulmonary veins.
• LTE4 acted as a partial agonist in pulmonary veins, blocking LTD4 and LTC4 effects.
• The dual antagonist BAY u9773 blocked LT contractions in both bronchial and venous preparations, indicating interaction with a second receptor (LT-2).

Conclusions:

• Pharmacological data strongly suggest the existence of a second cysteinyl leukotriene receptor (LT-2) in human pulmonary veins.
• LT-1 receptors, found in airways, are inhibited by standard LT-1 antagonists.
• LT-2 receptors, present in pulmonary veins, are resistant to LT-1 antagonists but are targeted by LTE4 and dual antagonists like BAY u9773, offering potential for novel therapeutic strategies.